Less Ads, More Data, More Tools Register for FREE

Friday broker round-up

Fri, 11th Oct 2019 12:40
(Sharecast News) - Whitbread: Deutsche Bank downgrades to sell with a target price of 3,650p.

discoverIE: Berenberg reiterates buy with a target price of 520p.

Spectris: Merrill Lynch upgrades to neutral with a target price of 2,500p.

Vesuvius: Merrill Lynch reiterates buy with a target price of 600p.

Bellway: UBS reiterates buy with a target price of 3,600p.

Anglo American: Jefferies reiterates buy with a target price of 2,200p.

Rio Tinto: Jefferies downgrades to hold with a target price of 4,700p.

Intercontinental Hotels Group: Deutsche Bank initiates at hold with a target price of 4,935p.

Big Yellow Group: Peel Hunt reiterates hold with a target price of 1,000p.

Admiral Group: Peel Hunt reiterates hold with a target price of 2,150p.

Mondi: UBS reiterates buy with a target price of 1,850p.

Filtrona: JP Morgan initiates with neutral and a target price of 8,600p.

GVC: JP Morgan initiates at overweight with a target price of 1,040p.

William Hill: JP Morgan initiates at neutral with a target price of 180p. Admiral Anglo American InterContinental Hotels Rio Tinto Bellway Whitbread Big Yellow Vesuvius Mondi DiscoverIE

Shares in this article

Related News

UK homebuilder Bellway says Iran war and political uncertainty cloud outlook
5 hours ago

UK homebuilder Bellway says Iran war and political uncertainty cloud outlook

* Company warns of slowing demand and rising building ​costs

Real Estate Bellway + 4 more shares
Bellway sticks with annual outlook but demand cools in April and May
7 hours ago

Bellway sticks with annual outlook but demand cools in April and May

(Alliance News) - Bellway PLC on Tuesday backed full-year profit guidance but noted the outlook beyond the current financial year remains uncertain, w...

LONDON BRIEFING: GSK agrees to buy US cancer drug maker Nuvalent
8 hours ago

LONDON BRIEFING: GSK agrees to buy US cancer drug maker Nuvalent

(Alliance News) - GSK agrees to buy US cancer treatment firm Nuvalent for USD10.6 billion, AstraZeneca advances its own weight-loss treatment while Be...

Corporate News WPP + 8 more shares